scholarly journals Inflammation and Behavioral Symptoms After Breast Cancer Treatment: Do Fatigue, Depression, and Sleep Disturbance Share a Common Underlying Mechanism?

2011 ◽  
Vol 29 (26) ◽  
pp. 3517-3522 ◽  
Author(s):  
Julienne E. Bower ◽  
Patricia A. Ganz ◽  
Michael R. Irwin ◽  
Lorna Kwan ◽  
Elizabeth C. Breen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Depressive Symptoms ◽  
Cancer Treatment ◽  
Sleep Disturbance ◽  
Plasma Levels ◽  
Inflammatory Markers ◽  
Breast Cancer Survivors ◽  
Early Stage ◽  
Self Report ◽  
Behavioral Symptoms

Purpose Fatigue, depression, and sleep disturbance are common adverse effects of cancer treatment and frequently co-occur. However, the possibility that inflammatory processes may underlie this constellation of symptoms has not been examined. Patients and Methods Women (N = 103) who had recently finished primary treatment (ie, surgery, radiation, chemotherapy) for early-stage breast cancer completed self-report scales and provided blood samples for determination of plasma levels of inflammatory markers: soluble tumor necrosis factor (TNF) receptor II (sTNF-RII), interleukin-1 receptor antagonist, and C-reactive protein. Results Symptoms were elevated at the end of treatment; greater than 60% of participants reported clinically significant problems with fatigue and sleep, and 25% reported elevated depressive symptoms. Women treated with chemotherapy endorsed higher levels of all symptoms and also had higher plasma levels of sTNF-RII than women who did not receive chemotherapy (all P < .05). Fatigue was positively associated with sTNF-RII, particularly in the chemotherapy-treated group (P < .05). Depressive symptoms and sleep problems were correlated with fatigue but not with inflammatory markers. Conclusion This study confirms high rates of behavioral symptoms in breast cancer survivors, particularly those treated with chemotherapy, and indicates a role for TNF-α signaling as a contributor to postchemotherapy fatigue. Results also suggest that fatigue, sleep disturbance, and depression may stem from distinct biologic processes in post-treatment survivors, with inflammatory signaling contributing relatively specifically to fatigue.

scholarly journals Cognitive Function After the Initiation of Adjuvant Endocrine Therapy in Early-Stage Breast Cancer: An Observational Cohort Study

2014 ◽  
Vol 32 (31) ◽  
pp. 3559-3567 ◽  
Author(s):  
Patricia A. Ganz ◽  
Laura Petersen ◽  
Steven A. Castellon ◽  
Julienne E. Bower ◽  
Daniel H.S. Silverman ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Depressive Symptoms ◽  
Endocrine Therapy ◽  
Test Performance ◽  
Early Stage ◽  
Self Report ◽  
Early Stage Breast Cancer ◽  
Linear Regression Models ◽  
Cognitive Complaints ◽  
Observational Cohort

Purpose This report examines cognitive complaints and neuropsychological (NP) testing outcomes in patients with early-stage breast cancer after the initiation of endocrine therapy (ET) to determine whether this therapy plays any role in post-treatment cognitive complaints. Patients and Methods One hundred seventy-three participants from the Mind Body Study (MBS) observational cohort provided data from self-report questionnaires and NP testing obtained at enrollment (T1, before initiation of ET), and 6 months later (T2). Bivariate analyses compared demographic and treatment variables, cognitive complaints, depressive symptoms, quality of life, and NP functioning between those who received ET versus not. Multivariable linear regression models examined predictors of cognitive complaints at T2, including selected demographic variables, depressive symptoms, ET use, and other medical variables, along with NP domains that were identified in bivariate analyses. Results Seventy percent of the 173 MBS participants initiated ET, evenly distributed between tamoxifen or aromatase inhibitors. ET-treated participants reported significantly increased language and communication (LC) cognitive complaints at T2 (P = .003), but no significant differences in NP test performance. Multivariable regression on LC at T2 found higher LC complaints significantly associated with T1 LC score (P < .001), ET at T2 (P = .004), interaction between ET and past hormone therapy (HT) (P < .001), and diminished improvement in NP psychomotor function (P = .05). Depressive symptoms were not significant (P = .10). Conclusion Higher LC complaints are significantly associated with ET 6 months after starting treatment and reflect diminished improvements in some NP tests. Past HT is a significant predictor of higher LC complaints after initiation of ET.

scholarly journals A Brief Review on Breast cancer treatment and current challenges

2021 ◽  
pp. 27-31
Author(s):  
Isha Shah ◽  
Nensi Raytthatha
Keyword(s):  
Breast Cancer ◽  
Side Effects ◽  
Cancer Treatment ◽  
Effective Treatment ◽  
Breast Cancer Survivors ◽  
Early Stage ◽  
Breast Cancer Treatment ◽  
Good News ◽  
Number Of Patients

Cancer is a global disease, so rational and effective treatment is needed. Breast cancer is one of the most common cancers in a woman and now the number of patients is increasing day by day. Therefore, development and research are underway for the effective treatment of breast cancer. Breast cancer treatment depends on the stage of cancer and the risk, based on this medical agents should be employed on patients to prevent breast cancer. In addition, breast cancer survival rates are rising which is good news for science but on the other hand the side effects of treatment present new challenges. An early-stage cancer diagnosis can save a patient's active or healthy life due to long-term and varied treatments that can be used for cancer otherwise breast cancer is a life-threatening disease. Breast cancer survivors not only have negative side effects of cancer treatment but also, have many other issues of previous treatment so it is a challenge for researchers. As a result, this review article deals with the effective treatment of breast cancer and its side effects. This review will help researchers better understand the long-term medical implications for breast cancer.

scholarly journals Acid-Producing Diet and Depressive Symptoms among Breast Cancer Survivors: A Longitudinal Study

Cancers ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 3183
Author(s):  
Tianying Wu ◽  
Fang-Chi Hsu ◽  
John P. Pierce
Keyword(s):  
Breast Cancer ◽  
Depressive Symptoms ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Early Stage ◽  
Net Endogenous Acid Production ◽  
Practical Strategy ◽  
Younger Age ◽  
Dietary Acid ◽  
Acid Load

The incidence of depression is two-to-three times higher in cancer survivors than the general population. Acid-producing diets may play important roles in the development of depression. Cancer survivors are more susceptible to acid-producing diets, yet few prospective studies have investigated the association of acid-producing diets with depression among breast cancer survivors. We leveraged a large cohort of 2975 early stage breast cancer survivors, which collected detailed dietary data via 24-h recalls. Potential renal acid load (PRAL) and net endogenous acid production (NEAP), two commonly used dietary acid load scores, were used to estimate acid-producing diets. Intakes of PRAL and NEAP were assessed at baseline and years one and four. Increased PRAL and NEAP were each independently associated with increased depression in the longitudinal analyses, after adjusting for covariates. The magnitude of the associations was stronger for PRAL than NEAP. Women with the highest quartile intakes of PRAL had 1.34 (95% CI 1.11–1.62) times the risk of depression compared to women with the lowest quartile. Furthermore, we also observed a joint impact of PRAL and younger age on depression, as well as a joint impact of PRAL and physical activity on depression. Decreasing the consumption of acid-producing diets may be a novel and practical strategy for reducing depressive symptoms among breast cancer survivors, especially those who are younger and have a sedentary lifestyle.

scholarly journals Clinical Predictors of Weight Gain in Early Breast Cancer Survivors

2021 ◽  
Vol 6 (2) ◽  
pp. 1
Author(s):  
Su-Ying Yu ◽  
Chii-Ming Chen ◽  
Chii-Ming Chen
Keyword(s):  
Breast Cancer ◽  
Weight Gain ◽  
Cancer Survivors ◽  
Cancer Treatment ◽  
Breast Cancer Survivors ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Healthy Weight ◽  
Breast Cancer Patients ◽  
Recurrence Rates

Aim: To identify risk factors for weight gain after two years of a breast cancer diagnosis.Background: Obesity in survivors of early-stage breast cancer has been associated with high disease recurrence rates and lower overall survival rates. Continuous weight gain is an indisputable phenomenon. Identifying factors at the early diagnosis and treatment phase that are associated with weight gain at 2 years later may help to develop further intervention for prevention obesity in breast cancer survivors.Method: A retrospective study was designed to review medical records of 1901 early-stage breast cancer survivors. Extracted data included demographics, past medical history, cancer treatment, tumor characteristics, BMI at diagnosis, and 24-month weights.Results: The sample had a mean age 50.3 (+10.7). Most of them were premenopausal, stage II and BMI ranging from 18.5 to 24 kg/m2 at diagnosis. A majority of them received mastectomy (65.9%), chemotherapy (68.8%), radiotherapy (64.6%) and hormone therapy (63%). At 24 months after surgery, the breast cancer patients gained a mean of 0.4kg; but 21.6% of them gained 5% or more. The breast cancer survivors those who were premenopausal at diagnosis, less-than-high-school education, receiving adriamycin agent, cyclophosphamide agent, and gaining 5% or more weight after surgery had significant higher risk to gain 5% or more at 2 years after diagnosis.Conclusion: Findings from our study suggested that the premenopausal women or those who receive less formal education have higher risk to gain weight after breast cancer treatment. Engagement to healthy weight management for these high risk groups are warranted

Depressive symptoms and inflammation are independent risk factors of fatigue in breast cancer survivors

2017 ◽  
Vol 47 (10) ◽  
pp. 1733-1743 ◽  
Author(s):  
C. Xiao ◽  
A. H. Miller ◽  
J. Felger ◽  
D. Mister ◽  
T. Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Depressive Symptoms ◽  
Cancer Survivors ◽  
Perceived Stress ◽  
Inflammatory Markers ◽  
Breast Cancer Survivors ◽  
Endocrine Treatment ◽  
Cancer Related Fatigue ◽  
Independent Risk Factors

BackgroundPsychosocial and inflammatory factors have been associated with fatigue in breast cancer survivors. Nevertheless, the relative contribution and/or interaction of these factors with cancer-related fatigue have not been well documented.MethodThis cross-sectional study enrolled 111 stage 0–III breast cancer patients treated with breast surgery followed by whole breast radiotherapy. Fatigue was measured by the total score of the Multidimensional Fatigue Inventory-20. Potential risk factors included inflammatory markers (plasma cytokines and their receptors and C-reactive protein; CRP), depressive symptoms (as assessed by the Inventory of Depressive Symptomatology–Self Reported), sleep (as assessed by the Pittsburgh Sleep Quality Index) and perceived stress (as assessed by the Perceived Stress Scale) as well as age, race, marital status, smoking history, menopause status, endocrine treatment, chemotherapy and cancer stage. Linear regression modeling was employed to examine risk factors of fatigue. Only risk factors with a significance level <0.10 were included in the initial regression model. A post-hoc mediation model using PROCESS SPSS was conducted to examine the association among depressive symptoms, sleep problems, stress, inflammation and fatigue.ResultsAt 1 year post-radiotherapy, depressive symptoms (p<0.0001) and inflammatory markers (CRP: p = 0.015; interleukin-1 receptor antagonist: p = 0.014; soluble tumor necrosis factor receptor-2: p = 0.009 in separate models) were independent risk factors of fatigue. Mediation analysis showed that depressive symptoms also mediated the associations of fatigue with sleep and stress.ConclusionsDepressive symptoms and inflammation were independent risk factors for cancer-related fatigue at 1 year post-radiotherapy, and thus represent independent treatment targets for this debilitating symptom.

scholarly journals Moderators of inflammation-related depression: a prospective study of breast cancer survivors

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Andrew W. Manigault ◽  
Patricia A. Ganz ◽  
Michael R. Irwin ◽  
Steve W. Cole ◽  
Kate R. Kuhlman ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Depressive Symptoms ◽  
Negative Affect ◽  
Cancer Survivors ◽  
Perceived Stress ◽  
State Anxiety ◽  
Inflammatory Markers ◽  
Breast Cancer Survivors ◽  
Childhood Adversity

AbstractInflammation has been shown to predict depression, but sensitivity to inflammation varies across individuals. Experimental studies administering potent pro-inflammatory agents have begun to characterize this sensitivity. However, risk factors for inflammation-associated depression in naturalistic contexts have not been determined. The present study examined key psychological and behavioral risk factors (state anxiety, perceived stress, negative affect, disturbed sleep, and childhood adversity) as potential moderators of the relationship between inflammation and depressive symptoms in a prospective longitudinal study of breast cancer survivors. Women with early stage breast cancer were recruited after completing primary cancer treatment (nfinal = 161). Depressive symptoms, inflammatory markers (CRP, IL-6, and sTNF-RII), and key risk factors were assessed post treatment (T1), at 6 and 12-month follow-ups (T2 and T3), and during a final follow-up (TF) 3−6 years after T1; childhood adversity was measured only at T3. Inflammatory markers were combined into a single inflammatory index prior to analyses. Women who reported higher levels of state anxiety, perceived stress, negative affect, and/or sleep disturbance at T1 (post-treatment) exhibited higher depressive symptoms at times when inflammation was higher than typical (interaction βs ranged from .06 to .08; all ps < .014). Results demonstrate the relevance of these risk factors for understanding inflammation-associated depression in a clinical context and could inform targeted strategies for prevention and treatment among at-risk populations.

Sign in / Sign up

Export Citation Format

Share Document